TY - JOUR T1 - ERS International Congress 2019 research highlights from Assembly 13 - A focus upon ESC/ERS guidance of acute PE, PH in relation to lung disease and PAH JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00304-2020 SP - 00304-2020 AU - Sheila Ramjug AU - Jason Weatherald AU - Sandeep Sahay AU - Johad Khoury AU - Vasile Foris AU - Chandran Nagaraj AU - Aleksandar Bokan AU - Laurent Godinas AU - Marion Delcroix Y1 - 2020/01/01 UR - http://openres.ersjournals.com/content/early/2020/09/01/23120541.00304-2020.abstract N2 - The European Respiratory Society's International Congress of 2019, held in Madrid, Spain had exciting sessions regarding the field of pulmonary vascular disease (PVD). The symposia related to the new ERS/ECS diagnosis and management of acute pulmonary embolism (PE) were well received, as were sessions of pulmonary hypertension (PH) related to lung disease, demonstrating the concept of PH not being the rarity that it was previously thought to be. The use of risk stratification in relation to pulmonary atrial hypertension (PAH) was heavily featured and the scientific sessions informing the respiratory community of potential biomarkers and targets for future therapies were thought provoking.In preparation of the upcoming innovative ERS International Virtual Congress in the autumn of 2020 we wanted to prepare a highlights article of the 2019 PVD sessions as a summary of current knowledge and practise.We have therefore, summarised the key points from the sessions pertaining to the new ERS/ESC guidance of the management of acute PE. We have also focused on prognostic factors and potential therapies in PH related to interstitial lung disease. Relating to PAH we have reviewed the symposia on risk stratification, along with the use on non-invasive measures and the sessions relating to biomarkers in PAH.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. Ramjug reports non-financial support from Janssen, grants and non-financial support from Actelion, during the conduct of the study.Conflict of interest: Dr. Weatherald reports grants, personal fees and non-financial support from Janssen Inc., grants, personal fees and non-financial support from Actelion, personal fees and non-financial support from Bayer, personal fees from Novartis, grants from Alberta Lung Association, grants from Canadian Vascular Network, grants from European Respiratory Society, grants from Canadian Thoracic Society, outside the submitted work.Conflict of interest: Dr. Sahay reports personal fees and non-financial support from Bayer Pharmaceuticals, personal fees and non-financial support from United Therapeutics, personal fees and non-financial support from Actelion Pharmaceuticals, grantsPersonal fees from LiquidiaConflict of interest: Dr. Khoury has nothing to disclose.Conflict of interest: Dr. Foris has nothing to disclose.Conflict of interest: Dr. Chandran has nothing to disclose.Conflict of interest: Dr. Bokan has nothing to disclose.Conflict of interest: Dr. Godinas has nothing to disclose.Conflict of interest: Dr. Delcroix reports grants and personal fees from null, personal fees from null, personal fees from null, personal fees from null, personal fees from null, personal fees from null, personal fees from null, outside the submitted work. ER -